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BACKGROUND: Tocotrienol-rich fraction (TRF) from palm oil has been shown to exhibit potent antioxidative properties in various pathological 
conditions. This study aimed to determine the antioxidative 
properties  of  TRF  on  the  plasma  and  erythrocyte 
membrane lipids composition in streptozotocin-induced 
diabetic rats. 
METHODS: Male Sprague-Dawley rats (n=40) were 
divided randomly into four groups of 10, which were a 
normal group, a normal group with TRF, a diabetic group, 
and a diabetic group with TRF. Following four weeks of 
treatment, lipids compositions in the plasma and erythrocyte 
membrane were investigated. 
RESULTS: TRF significantly reduced the plasma total 
cholesterol, to that in the diabetic group. In addition, 
supplementation of TRF was able to reduce the very low 
density lipoprotein cholesterol (VLDL-C), triglycerides 
levels in treated diabetic rat although no significant different 
was observed when compared with untreated diabetic rats 
alone. Furthermore, TRF supplementation showed increased 
the levels of phosphatidylinositol, phosphatidylserine, 
and total phospholipid levels in diabetic rats. However, 
the linoleic acid (18:2) levels were reduced in diabetic 
rats compared to the control group, and the eicosadienoic 
acid (20:2) levels were significantly increased by TRF 
supplementation in diabetic rats. 
CONCLUSION: Supplementation with 200 mg/kg TRF 
improves dyslipidemia and that TRF, therefore, might 
have protective effects against oxidative damage of 
phospholipids. This study also showed the antioxidative 
properties of TRF on the erythrocyte membrane lipids 
composition, in particular, its protective effects against 
peroxidation of unsaturated fatty acids.
KEYWORDS: antioxidative property, cholesterol, fatty 
acids, phospholipids, tocotrienol-rich fraction
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Abstract
Introduction
Various studies showed that antioxidant vitamins and 
supplements can reduce the markers indicative of oxidant 
stress and lipid peroxidation in diabetic subjects and 
animals.(1) The nutritional role of vitamin E is clearly 
that of a biological antioxidant. Vitamin E is believed to 
have basic functional importance in the maintenance of 
membrane integrity in almost all cells of the body. It reduces 
free radicals and therefore protects against the deleterious 
reactions of highly reactive oxidizing species.(2)
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 Palm oil, annatto, rice bran oil, oats, hazelnuts 
and maize are rich natural sources of vitamin E, mainly 
tocotrienol.(1) A better understanding of the biological 
significant of tocotrienols should contribute not only to 
the knowledge of discovering the health-giving properties 
of tocotrienols, but also towards more effective potential 
therapeutic agent in the prevention of several pathological 
condition and maintenance of human health. A number of 
health-related  biological  properties  of  tocotrienols  have 
been identified, including its anticancer, anticholesterolemic, 
antihypertensive, antioxidant, immunomodulatory and 
neuroprotective properties.(3) In addition to its activities, 
tocotrienol-rich fraction (TRF), extracted from palm oil, 
inhibits cholesterol synthesis by suppressing 3-hydroxy-
3-methylglutaryl coenzyme A reductase in various cells.
(4) Currently TRF addressed as anti-apoptotic and anti-
inflammatory agents.(5) 
 Recent review showed that tocotrienols have more 
antioxidant and free radical scavenging properties than 
tocopherols.(6) Thus, this study aimed to determine 
the antioxidant properties protective effects of TRF on 
plasma and erythrocyte membrane lipids composition of 
streptozotocin (STZ)-induced diabetic rats. 
Methods
Animals and Ethics Statement
Forty male Sprague-Dawley rats, aged 8-10 weeks 
and weighed 200-250g, were provided by Laboratory 
Animal Resources Unit, Faculty of Medicine, Universiti 
Kebangsaan Malaysia. They were housed in plastic cages 
(two rats per cage) with wood chips for bedding. and were 
fed standard diet (mouse pellet 702 P, Gold Coin Sdn. 
Bhd., Selangor, Malaysia) and tap water ad libitum. The 
animals were acclimatized to standard laboratory conditions 
(temperature 25°C, with light-darkness cycles of 12 hour) 
for one week before the commencement of the experiments. 
The recommendation of University Kebangsaan Malaysia 
Animal Ethics Committee (UKMAEC) for the care and 
use of the animals were followed throughout the study and 
the approval code is as follow (UKMAEC No.: FSKB\
BIOMED\2010\JAMALUDIN\20-MAY\304).
TRF Supplementation in Rats
Rats were randomly divided into four groups of 10 rats, 
as follows: normal rats served as control group (Group 
1), normal rats supplemented with TRF (Group 2), 
non-treated diabetic group (Group 3), and diabetic rats 
supplemented with TRF (Group 4). Induction of diabetes 
was achieved following an overnight fasting by a single 
intravenous injection (via tail vein) of freshly prepared STZ 
(streptozotocin) (Sigma, St, Louis, USA) at a dose of 45 
mg/kg body weight (BW) which was freshly dissolved in 
normal saline. Three days later, blood collected via tail vein 
and glucose concentration was measured by a strip-operated 
blood glucose sensor (Companion 2, Medisense Ltd., and 
Birmingham, UK). Several studies reported that induction 
of experimental diabetes in the rat using STZ is very 
convenient and simple to use.(7,8) STZ injection leads to 
the degeneration of the Langerhans islets beta cells and lead 
to the reduction of insulin secretion in STZ induced diabetic 
rats. This mechanism cause increased in plasma glucose 
levels, which lead to diabetes condition.(9,10) Clinically, 
symptoms of diabetes are clearly seen in rats within 
2-4 days following single intravenous or intraperitoneal 
injection of 45 mg/kg STZ. The results of fasting blood 
glucose (FBG) presented in this study indicated that STZ-
induced diabetes was successfully achieved as evidenced 
by significantly high level of blood glucose in diabetic 
rats. This could be due to the inhibition of insulin secretion 
resulting from injection of STZ. Our study showed higher 
levels of glycemic status and food and fluid intake as well as 
decreased body weight, which had been reported in the past. 
Rats with blood glucose levels >7.0 mmol/L were included 
in the study.(11,12) The dose of TRF, which was obtained 
from SIME DARBY Malaysia, was administered orally 
at a dose of 200 mg/kg body weight /day (7,9) throughout 
the feeding period of four weeks and the supplementation 
begun on the same day. Following four weeks of TRF 
supplementation, the rats were fasted overnight, and blood 
samples were collected by cardiac puncture under diethyl 
ether-induced deep anesthesia. 
Preparation of Erythrocytes Membranes and Extraction 
of Lipids
Erythrocytes were centrifuged at 4000 rpm for 15 min at 
4°C. The plasma was transferred into new 1.5 mL Eppendorf 
tubes and frozen until further use at -80°C. Extraction of 
erythrocytes membranes was performed according to 
the method described by Dodge and Phillips.(13) The 
erythrocytes-containing pellet was washed twice with cold 
(4°C) 9% normal saline (pH 7.4) (5/1 v/v). For the third wash, 
5% Trolox (97% 6-hydroxy 5, 7, 8-tetramethylchroman-
2-carboxylic acid) in normal saline was used in order to 
prevent oxidation of the membrane fatty acids. Lipids 
were extracted from the erythrocytes membranes using the 
method described previously.(14)
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Determination of The Lipids Composition in The 
Plasma High-density Lipoprotein (HDL), Low-density 
Lipoprotein (LDL), VLDL, and Total Cholesterol (TC)
Plasma TC, HDL-C, and LDL, VLDL-C were quantified 
using a commercial enzymatic assay kit (Cat No. K613-100, 
Biovision Inc, Milpitas, USA). The readings for samples 
and the standard were determined using a fluorescence plate 
reader equipped with an excitation wavelength/emission 
wavelength (Ex/Em) of 538/587 nm (SkanIt Software, 
Thermo Fisher Scientific Inc, Waltham, USA).
Measurement of Plasma Triglyceride (TG) 
TG levels were measured using an enzymatic-based 
hydrolysis method (Cat No. T532-480, Teco diagnostics, 
Anaheim, USA). TG are hydrolyzed by a lipase, into glycerol. 
The glycerol concentration is then determined using an 
enzymatic assay leading to the formation of a quinoneimine 
dye. Amount of dye produced was determined using a 
spectrophotometer (520 nm) and is directly proportional to 
the concentration of TG in the samples.
Measurement of Plasma Total Lipid 
The total amount of lipids in the plasma was quantified 
using a sulfo-phospho-vanillin colorimetric method (Cat 
No. T526-480, Teco diagnostics). The amount of the purple 
complex formed was determined using a spectrophotometer 
at 530 nm.
Determination of Erythrocyte Membrane Cholesterol and 
Phospholipids Using Liquid Chromatography-tandem 
Mass Spectrometry (LC-MS/MS) Instrumentation
We used a Thermo Scientific C18 SIRI Dionex Ultimate 
3000 liquid chromatography system (Shimadzu CL 
09115047, Shimadzu, Kyoto, Japan), directly coupled to the 
mass spectrometer system MS (Bruker/microTof Q, Bruker 
Daltonics, Billerica, USA), equipped with an electro spray 
ionization (ESI) source. We used the positive mode on a 150 
x 2 mm Phenomenex C18 reversed-phase column (2.0 mm 
x 4.6 mm) of 5-µm particle size. LC-MS was performed 
using an integrated pre column (SepServ, Berlin, Germany). 
The column was maintained at 60°C and we used a mobile 
phase flow-rate of 0.3 mL/min. MS data were acquired over 
a scan range of 50-1500 m/z. The other parameters used are 
as follows: Set Capillary 4000 V, End Plate Offset -500 V, 
Set Collision Cell RF 250.0 Vpp. 
Erythrocyte Membrane Phospholipids Analysis
The separation of phospholipids was performed using the 
method conducted by Alefee.(15) The mobile phase was 
composed of solvent A (0.1% formic acid in water) and 
solvent B (methanol, MeOH). Both were freshly prepared 
prior to analysis. The solvents and the flow rates used were 
as shown in Table 1. The lipids extracted were filtered 
using a high performance liquid chromatography (HPLC) 
(45-µm) filter prior to injection into the LC-MS system. 
Separation was carried out using a flow rate of 0.3 mL/min 
and an evaporative light scattering detector was used. Data 
were analyzed using the Bruker Daltonics software (version 
3.4) to quantify the average of phospholipids levels in µg/
mg of proteins. 
Time 
(min)
Solvent A 
(%)
Solvent B 
(%)
Flow-rate 
(mL/min)
0 90 10 0.3
5 90 10 0.3
15 0 100 0.3
25 0 100 0.3
26 90 10 0.3
30 90 10 0.3
Table 1. Solvent gradient and flow rates used for 
separation of phospholipids by LC-MS.
Erythrocyte Membrane Cholesterol Analysis
The lipid extracts were resuspended in 1 mL of ethanol 
and homogenized using a vortex for 15 sec. Standard 
concentrations ranging from 0, 10, 20, 40, 80 and 100 μg 
of lipids were (Table 2). After resuspension, the samples 
were filtered using an HPLC (45-µm) filter and injected 
into the LC-MS system. We followed the same procedure 
as described for erythrocyte membrane phospholipids 
analysis. The cholesterol concentration was calculated as 
µg/mg protein. The retention time for cholesterol was 15 
min.
Standard Solution 
Concentration
(µg/mL)
Volume of Stock 
Cholesterol
(mL)
Volume of 
Ethanol
(mL)
0 0 2
10 0.2 1.8
20 0.4 1.6
40 0.8 1.2
80 1.6 0.4
100 2 0
Table 2.  Cholesterol standard concentrations.
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Erythrocyte Membrane Fatty Acid Composition 
Analysis: Preparation of Fatty Acid Methyl Esters from 
Lipids with Boron Fluoride-methanol 
Prior to gas chromatography (GC), methylation of fatty acids 
was carried out using a boron trifluoride-methanol reagent 
in accordance with the method described by Morrison and 
Smith.(6) Briefly, the extracted lipids were evaporated to 
dryness under nitrogen in a centrifuge tube. Then, 1 mL 
of the boron fluoride-methanol reagent was added under 
nitrogen gas, and the tubes were closed with the screw cap. 
The tubes were then heated at 100°C in a boiling water 
bath for 2 min. The esters were extracted using 2 volumes 
of pentane and 1 volume of water. After homogenization, 
the samples were centrifuged until both layers were well 
separated and clear (this can give up to 97-99% extraction 
of the esters). The upper layer, containing the pentane and 
extracted lipids, was transferred into a new test tube, and 
the total fatty acids composition was determined by GC-MS 
system.
GC-MS Instrumentation
For the gas chromatography-mass spectrometry (GC/MS) 
analysis, we used an Agilent 7890A Gas Chromatograph 
(GC) directly coupled to the mass spectrometer system 
(MS). The parameters were as follows: Agilent 5975C inert 
inert mass selective detector (MSD) with triple-axis detector, 
column model SP-2380, length 30 m, diameter 0.25 mm, 
stationary phase, stabilized, poly (90% biscyanopropyl/10% 
cyanopropylphenyl siloxane, film thickness 0.25 µm, 
Corporation Supelco Analytical. The fatty acids composition 
was determined according to previously described method.
(17) After injecting 1 µL of each FAME extract into the 
GC system. The oven temperature was programmed to go 
up from 70º to 160°C at 25°C/min and then from 160°C to 
250°C at 3°C/min. The temperature was then maintained at 
250°C for 20 min. The helium gas flow rate used was 1.5-
2.0 mL/min, the flame ionization temperature 300°C and the 
temperature of the injector was 240°C. 
Identification of Peaks
The MSD Chemstation was used to analyze the GC 
chromatograms. A library search was carried out using the 
NIST/EPA/NIH Version 2.0, and the results were combined 
in a single peak table.
Statistical Analysis
The data were analyzed using SPSS version 16 (SPSS Inc., 
Chicago, USA). Shapiro-Wilk test was used to check the 
normality of the variable. Accordingly, ANOVA were used 
to analyze data follow normal behaviour of distribution 
pattern, followed by post hoc LSD multiple comparison 
test were used to estimate the significance different between 
groups. While, Kruskal-Wallis-one way ANOVA test were 
used to analyze data follow non-normal behaviour of 
distribution pattern. The difference between groups was 
considered significant when p<0.05.
Body Weight, Food and Water Consumption 
Throughout  four weeks of study, the food and water intake 
were markedly increased in diabetic groups (diabetic and 
diabetic with TRF) when compared to those normal groups. 
The average of food intakes for all diabetic groups were 
642.1-902 g per week while normal groups showed an 
average of 230.5-324.9 g per week. Water intakes for all 
diabetic groups had average of 350-600 mL per week, while 
normal groups showed an average of 160-290 mL per week. 
The consumptions of food and water were calculated per 
cage so that statistical result would not be influenced. Body 
weight for all experimental groups was recorded throughout 
the period of four week. Initially, all experimental groups 
had similar body weights, at the end of the study period both 
diabetic groups (untreated diabetic and diabetic with TRF) 
showed significantly loss of body weight when compared to 
the normal groups (Figure 1).
Effects of TRF Supplementation on Plasma Lipoprotein 
Profiles (HDL-C, LDL-C, VLDL-C) 
Untreated diabetic group showed significantly lower plasma 
HDL-C concentration when compared to the control group 
(p=0.03). However, TRF-treated diabetic rats showed 
significantly higher levels of HDL-C when compared to 
the untreated diabetic group (p=0.002). Plasma LDL-C 
levels were higher in diabetic rats but none significantly 
different when compared to the control groups, TRF-treated 
diabetic rats showed a significantly lower level of LDL-C 
when compared to the untreated diabetic rats (p=0.0001). 
The levels of VLDL-C were significantly higher in both 
treated and non-treated diabetic groups compared to the 
control group (p=0.0001 for both). However, TRF treatment 
was able to reduce the VLDL-C levels in treated diabetic 
rat although no significant different was observed when 
compared with untreated diabetic rats alone (Figure 2A, 2B 
and 2C).
Results
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Figure 1. Effects of food consumption, water consumption and 
rats body weights in different groups of study. Normal group 
consist of  heatlthy rats;  Normal+TRF  supplemented  with  TRF  at 
dose of 200 mg/kg body weight; Diabetic group received a single IV 
injection of STZ (45mg/kg) body weight; Diabetic+TRF received a 
single IV injection of STZ (45mg/kg) and supplemented with TRF at 
dose of 200mg/kg. *: significantly different from the normal group.
Effects of TRF Supplementation on Plasma Levels of 
TC, TG and Total Lipids
The concentration of TC was significantly higher in the 
diabetic group compared to the control group (p=0.0001). 
TRF treatment induced a significant decrease in the 
concentration of TC in diabetic rats (p=0.0001), restoring 
the  levels of TC to normal conditions. The concentration 
of plasma TG was significantly higher in TRF-treated and 
non-treated diabetic rats compared to the control group 
(p=0.0001) however, TRF treatment did not significantly 
affect the concentration of TG in diabetic rats. Plasma 
total lipids levels were markedly increased in untreated 
diabetic rats compared to the control group (p=0.0001) and 
TRF significantly reduced the plasma total lipids levels of 
diabetic rats (p=0.0001) (Figure 2D, 2E and 2F).
Effects of TRF Supplementation on Erythrocyte 
Membrane Lipid Composition
STZ-induced diabetic groups (untreated and TRF-treated 
diabetic rats) showed significantly increased levels of 
erythrocyte membrane cholesterol when compared to the 
control group (p=0.001 and p=0.01, respectively). However, 
TRF did not significantly lower the levels of erythrocyte 
membrane cholesterol in diabetic rats (Table 3). 
 The composition of phospholipids 
(phosphatidylinositol, phosphatidylserine, phosphatidyl-
ethanolamine, and phosphatidylcholine in erythrocytes 
membranes were analyzed in Table 3. Our results show that 
there were lower levels of phosphatidylcholine and higher 
levels of phosphatidylethanolaminein the diabetic group 
compared to the control group. Total phospholipids levels 
were also significantly decreased in both untreated and 
TRF-treated diabetic rats compared to TRF-treated normal 
rats (p=0.02 and 0.04 respectively). 
 Meanwhile, the composition of the analyzed 
erythrocytes membranes fatty acids are shown in Table 4. 
Discussion
The findings of this study showed that the plasma levels of 
TC, LDL-C, VLDL-C and TG were elevated in STZ-induced 
diabetic rats compared to the control group, while the levels of 
HDL-C were decreased. These findings were in accordance 
with previous report.(18) Our previous study showed that a 
daily oral supplementation of 200 mg/Kg of TRF of palm 
oil had the beneficial effect of reducing levels of oxidative 
stress  markers by an inhibition of lipid peroxidation and 
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Figure 2. Effects of TRF supplementation on various parameters. A: the effect on HDL-cholesterol; B: the effects on LDL-cholesterol; 
C: the effect on VLDL-cholesterol; D: the effect on total cholesterol; E: the effects on triglyceride; F: the effects on total lipid. Normal 
group consist of  heatlthy rats; Normal+TRF supplemented with TRF at dose of 200 mg/kg body weight; Diabetic group received a single 
IV injection of STZ (45mg/kg) body weight; Diabetic+TRF received a single IV injection of STZ (45mg/kg) and supplemented with TRF 
at dose of 200mg/kg. a: significantly different from the normal group; b: significantly different from the normal+TRF group; c: significantly 
different from the diabetic group.
an increase in the levels of antioxidant defense system. 
These results suggest that TRF supplementation plays an 
important role in reducing oxidative stress-induced diabetes 
mellitus.(12)
 The hypocholesterolemic activity of tocotrienols 
has recently received much attention, mainly because 
of their well-established ability to reduce cholesterol 
biosynthesis. Interestingly,  in   the  present  study,  the 
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Phospholipids Protein
(µg/mg) Normal Group Normal+TRF Diabetic Group Diabetic+TRF
Phosphatidylcholine 26.76±9.30 23.79±9.00 15.12±5.60a 24.44±11.60
Phosphatidylinositol 37.29±27.10 64.13±44.20 18.60± 3.80b 25.32±13.50b
Phosphatidylserine 14.03±10.00 24.74±6.80a 6.91±2.90b 14.20±8.19b
Phosphatidylethanolamine 86.89±15.20 76.82±11.20 91.95±15.70 78.45±24.20
Total phospholipid 165.00±42.60 189.40±57.50 132.60±12.70b 142.50±35.00b
Cholesterol  55.73±11.50 57.24±11.30 97.99±12.00a,b 82.73±19.30a,b
Cholesterol/phospholipid ratio 0.33±0.05 0.30±0.04 0.73±0.05a,b 0.58±0.08a,b  
Table 3.  Phospholipid compositions of erythrocyte membrane from various experimental groups.
Results are expressed as means±SD. a: significantly different from the normal group at p<0.05, b: significantly 
different from the normal+TRF group at p<0.05.
dietary supplementation of TRF (200 mg for four weeks) 
significantly reduced the plasma levels of TC and LDL-C 
and increased the levels of HDL-C in diabetic rats. Increases 
in plasma HDL-C have been associated with reduced risk 
for coronary heart disease.(19) These results suggest that 
TRF is a protective agent for many diseases including 
atherosclerosis and coronary heart disease. This also 
confirms the potential of tocotrienols as effective nutritional 
agents to treat high cholesterol.
 In the present study, increased levels of TG were 
observed in the untreated diabetic group compared to the 
control group. However, dietary supplementation of TRF 
in diabetic rats had no effect on the levels of TG, as well 
as VLDL-C. It is possible that TRF supplementation for 4 
weeks at a dose of 200 mg/kg is not enough to restore the 
levels of VLDL-C and TG at a normal level. Furthermore, 
different tocotrienol subtypes possess various degrees 
of hypolipidemia activity. The results of this study are 
consistent with previous study.(20) 
 Several studies aiming at characterizing the lipids 
composition of erythrocytes membranes have been 
previously conducted in diabetic humans and animal models.
(21,22) In the present study, we observed an alteration of 
membrane cholesterol, membrane phospholipids, and TC/
total phospholipids ratio in diabetic erythrocytes compared 
to erythrocytes from the normal group. An increase in 
membrane cholesterol reflects the increase of the serum 
cholesterol concentration (23), which was confirmed in 
the present study. Both, phospholipids and cholesterol, are 
accountable for the changes of the erythrocyte membrane.
(24) They are also responsible for their biconcave shape 
and basic structural integrity. In this study, membrane 
fluidity was further evaluated by calculating cholesterol and 
phospholipid (CH/PL) ratios. The diabetic groups showed 
higher erythrocyte CH levels, leading to an increased 
CH/PL ratio and indicating an increase of the membrane 
rigidity.(25) Surprisingly, we found that TRF treatment did 
not significantly reduce the concentration of cholesterol 
in erythrocytes membranes in diabetic rats. One possible 
explanation for the lack of cholesterol lowering properties 
of tocotrienols in vivo may be due to poor absorption or 
rapid clearance from plasma. The controversial effects of 
tocotrienols were attributed to the presence of α-tocopherol, 
which was shown to attenuate the effect of the cholesterol-
lowering action of tocotrienols in chickens.(26) 
 Phosphatidylcholine is an important for normal 
cellular membrane composition and repair. It is also the 
major delivery form of the essential nutrient choline. One 
set of roles is an important substrate of synthesis of the 
neurotransmitter acetylcholine, and having the function of 
nourishing the brain and improving intelligence.(27)
 Our results show that there were lower 
levels of phosphatidylcholine and higher levels of 
Phosphatidylethanolamine in the diabetic group compared 
to the control group. These findings are in agreement 
with  a  previous  study,  which  suggested  that this 
phenomenon may be due to a lower rate of conversion 
of phosphatidylethanolamine into phosphatidylcholine 
(25), or a down-regulation of choline-phosphatecytidyl 
transferase, an enzyme regulating phosphatidylcholine 
synthesis.  Increased  phosphatidylethanolamine  levels 
in diabetics have been observed in all cell types studied, 
while sphingomyelin and phosphatidylcholine levels were 
decreased in platelets.(28)
 Phosphatidylinositol is an integral part of cellular 
and sub-cellular membranes. It exerts its effect through 
membrane-mediated events.(29) It also modulates the 
activity of several important membrane-bound enzymes 
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Normal Group Normal+TRF Diabetic Group Diabetic+TRF
14:00 (Myristic acid) 1.63±0.87 1.80±1.20 2.83±1.80 1.21±0.64c
16:00 (Palmitic acid) 8.70±6.90 8.60±6.80a 17.30±7.10a,b 18.4±5.90a,b
17:00 (Heptadecanoic Acid) 1.92±1.60 1.84±1.40c 8.58±6.50a,b 5.95±2.30
18:00 (Stearic Acid) 7.82±2.90 6.16±2.20 9.81±3.72 7.08±1.60
20:00 (Arachidic Acid) 2.45±1.40 4.09±2.30 3.42±1.04 1.56±0.43b
22:00 (Docosanoic acid) 12.60±5.20 12.07±5.40 3.67±0.59a,b 5.44±1.50a,b
Total 35.10±6.80 34.50±6.10 45.60±17.10a 39.60±10.30 
16:1 c9 (Palmitoleic acid) 1.46±0.77 2.79±1.10 2.50±1.20 3.88±1.60
18:1 c9 (Oleic acid) 8.00±2.90 8.56±2.50 1.48±0.54a,b 1.91±1.00a,b
20:1 c 11 (11-Eicosenoic acid) 3.04±1.50 1.13±0.41a 1.76±0.53 2.58±1.10
Total 12.51±3.80 12.50±3.70 5.74±1.5a,b 8.38±4.20
18:2 (Linoleic acid) 17.77±6.20 17.46±6.90 5.95±2.50a,b 9.27±3.40a,b,c
18:3 (Alpha-linolenic acid) 1.64±0.61 0.92±0.35a 0.80±0.51a 1.05±0.53
20:2 (Eicosadienoic acid) 0.64±0.17 0.92±0.53 1.38±0.48 2.60±0.27a,b,c
Total 20.06±6.60 19.30±7.00 8.14±2.10a,b 13.01±3.30a
Fatty Acids (weight %)
Saturated fatty acids (SFA)
Monounsaturated fatty acid (MUFA)
Polyunsaturated fatty acid (PUFA) 
Table 4. Fatty acid compositions of erythrocyte membrane from various experimental groups. 
Results are expressed as means±SD. a: significantly different from the normal group at p<0.05, b: significantly 
different from the normal+TRF group at p<0.05; c: significantly different from the diabetic group at p<0.05
(e.g., Na+-K+ ATPase, alkaline phosphatase, acetyl-CoA 
carboxylase and tyrosine hydroxylase) as well as having 
a role in the insulin signal transduction pathway.(30) It 
is now clear that phosphatidylinositol affects lipoprotein 
metabolism both by controlling interfacial interactions 
and uniquely regulating intracellular signaling pathways. 
PI therefore directly acts to block the synthesis and 
storage of cholesteryl ester in the blood stream.(31) In 
addition, phosphatidylinositolappeared to stimulate reverse 
cholesterol transport (RCT) by promoting a 30-fold increase 
in the rate of clearance of free cholesterol (FC) from the 
circulation.(32) Furthermore previous study shows that 
phosphatidylinositol also stimulates RCT and results in a 
net elimination of cholesterol from the body.
 Furthermore, this study showed that the levels of 
phosphatidylinositol were significantly reduced in untreated 
diabetic group compared to control group. It has been 
reported that phosphatidylinositol are rich in arachidonic 
acid and serve as a significant source of eicosanoids.(33) 
Interestingly, our results show changes in arachidonic acid 
levels in erythrocytes membranes. The changes in the lipids 
and phospholipids composition of erythrocytes membranes 
observed in the present study may induce changes in the 
physico-chemical properties of the erythrocyte membrane 
as well as its fluidity/rigidity.(34) 
 This study provides evidence that the erythrocyte 
membrane of diabetic rats contains an abnormal lipid 
matrix. The enrichment in cholesterol and decreasing of 
total phospholipids in erythrocytes membranes of diabetic 
rats shown in this study, suggests that the trans-bilayer lipid 
distribution is probably impaired in diabetic subjects. It 
is also noteworthy that the levels of saturated fatty acids 
were higher in the erythrocytes of diabetic rats than in the 
erythrocytes of normal rats.  
 Fatty acid residues, namely saturated fatty acids 
(SFA), monounsaturated fatty acid (MUFA), and 
polyunsaturated fatty acid (PUFA) can affect membrane 
fluidity and permeability.(35) The present study showed 
that the erythrocyte levels of total SFA were higher in the 
untreated diabetic group compared to the control group. 
This increase most likely results from the hyperglycemia 
observed in diabetic patients. Interestingly, TRF treatment 
induced a decrease of the heptadecanoic acid (17:00) and 
stearic acid (18:00) levels in diabetic rats, which suggests 
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that TRF has antilipidemic effects. However, the levels 
of docosanoic acid (22:00) were significantly lower in 
the diabetic groups. The  changes detected in diabetic 
erythrocyte membrane composition, particularly in palmitic 
acid (C16) levels, could help deciphering the biophysical 
properties of membranes, such as the mechanisms regulating 
their fluidity.(36) Previous study reported that elevated 
C16:0 fatty  acids  were  positively  linked  with  LDL-C 
(37), whose levels were increased in the diabetic group in 
the present study.
 In this study, we showed that both diabetic groups 
(untreated and TRF-treated diabetic rats) showed 
significantly lower levels of oleic acid 18:1 c9 compared to 
the normal group, which might be due to the reduced activity 
of stearoyl CoA desaturase (SCD), enzyme responsible 
for MUFA synthesis, in diabetic conditions. PUFA are 
important fatty acids in membrane fluidity and flexibility.
(38) Our study showed that alpha-linolenic (ALA 18:3n-6) 
and linoleic acid (LA, 18:2n-6) levels were significantly 
lower in the diabetic group compared to controls, which 
is consistent with a previous study.(39) Interestingly, we 
observed that TRF treatment also significantly increased 
the levels of eicosadienoic acid (20:2) in diabetic rats. The 
diabetic group showed lower total MUFA and PUFA. This 
may be due to defects in the metabolism of essential fatty 
acids (EFA). TRF supplementation was able to increase 
total PUFA levels and reduce the difference in lipid fatty 
acid composition between the diabetic and control animals, 
which is consistent with the reported antioxidative properties 
of vitamin E.(40) 
Conclusion
Our results indicate that daily oral supplementation of 200 
mg/kg of TRF for 4 weeks improved dyslipidemia in STZ-
induced diabetic rats. Moreover, our data demonstrated the 
protective effects of TRF against peroxidation of erythrocyte 
membrane lipids, in particular of unsaturated fatty acids, 
and suggest the protective effects of TRF against oxidative 
stress damage. 
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